NCT02381561 2026-03-19
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
23 trialsNCT05211323 2026-03-19
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT03408665 2026-03-18
STEREOLIVER
Centre Oscar Lambret
Phase NA Active not recruiting
NCT03028311 2026-03-10
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05743842 2026-03-09
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06084884 2026-03-09
ATHENA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT05953337 2026-03-04
Radioembolization Trial Utilizing Eye90 Microspheresâ„¢ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical
Phase NA Active not recruiting
NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT04008797 2026-02-27
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT05438420 2026-02-24
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
Phase 1/2 Active not recruiting
NCT04258813 2026-02-20
ONE TEAM
Duke University
Phase NA Active not recruiting
NCT05883644 2026-02-18
SIERRA
AstraZeneca
Phase 3 Active not recruiting
NCT02954094 2026-02-06
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Target PharmaSolutions, Inc.
Active not recruiting
NCT03937830 2026-02-05
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04736121 2026-02-03
DOORwaY90
Sirtex Medical
Phase NA Active not recruiting
NCT07362264 2026-01-23
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1 Active not recruiting
NCT04377932 2026-01-21
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT03778957 2026-01-16
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT00582647 2026-01-15
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT04573881 2026-01-12
#HOPE4LIVER
HistoSonics, Inc.
Phase NA Active not recruiting
NCT01494324 2026-01-02
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting